Munich-based techbio firm mbiomics has closed the final tranche of its Series A financing, securing an additional €12 million. This brings the total capital raised to €30 million, with continued backing from investors MIG Fonds and Bayern Kapital. The funds will advance the company's scalable microbiome therapeutics, particularly its lead candidate for advanced melanoma.
Advancing Microbiome Therapeutics
Founded in 2020, mbiomics develops Live Biotherapeutic Products (LBPs), which are oral therapies of live bacterial strains. This approach overcomes the limitations of Faecal Microbiota Transplants (FMTs), which suffer from inconsistency and scalability issues. The company aims to transform microbiome modulation into a reliable, pharmaceutical-grade treatment strategy for severe diseases.
At its core is a proprietary platform that enables the rational design of complex microbial consortia. The company leverages artificial intelligence, machine learning, and advanced analytics to engineer these communities with precision. This technology addresses the engineering challenge of producing consistent and scalable microbiome therapeutics for clinical use.
Focus on Oncology and Beyond
The company's lead candidate, MBX-116, is a co-therapy for second-line melanoma patients receiving immune checkpoint inhibitors. Clinical evidence suggests modulating the gut microbiome can significantly improve patient response rates to these cancer treatments. Mbiomics aims to validate this potential and improve outcomes for this specific patient population.
With the new capital, mbiomics will accelerate IND-enabling studies and establish Good Manufacturing Practice (GMP) compliant production. This investment paves the way for the clinical evaluation of MBX-116. The company is targeting 2027 for the initiation of a Phase 1B clinical trial.
Beyond its initial oncology focus, mbiomics is building a broader pipeline with applications in other critical areas of medicine. The company is actively exploring treatments for autoimmune and neurodegenerative diseases. This expansion is driven by growing research into the pivotal role of the gut-immune and gut-brain connections.
Strategic Investment and Market Position
The €30 million Series A round marks a milestone, signaling the company's transition from platform development to clinical execution. CEO Dr. Johannes B. Woehrstein emphasized the focus is now on advancing MBX-116 towards clinical evaluation. This shift underscores the company's commitment to translating its innovations into patient benefits.
Investor confidence remains strong, with Dr. Matthias Kromayer of MIG Capital praising the team's impressive progress. He highlighted the company's momentum as it moves toward clinical validation and continues to build its therapeutic pipeline. This support validates the company's scalable approach to microbiome science and its potential market impact.
While the biotherapeutics space includes competitors, mbiomics sets itself apart with its integrated technology stack. The company's key differentiator is its ability to design, analyze, and manufacture complex microbial consortia at scale. This comprehensive approach positions it to overcome a key bottleneck that has historically limited the field.
The successful €30 million Series A financing positions mbiomics to enter its next growth phase as a clinical-stage company. By combining its AI-driven platform with a focus on scalable manufacturing, the company is poised to address unmet needs in oncology and beyond. This advancement strengthens its potential to become a leader in developing next-generation microbiome therapeutics.